Literature DB >> 15663999

Intervention thresholds for osteoporosis in the UK.

John A Kanis1, Frederik Borgstrom, Niklas Zethraeus, Olof Johnell, Anders Oden, Bengt Jönsson.   

Abstract

The aim of this study was to determine the threshold of fracture probability at which interventions became cost-effective in women based on data from the UK. We modelled the effects of an intervention costing pound 350 per year given for 5 years that decreased the risk of all osteoporotic fractures by 35% followed by a waning of effect (offset time) for a further 5 years. Sensitivity analyses included a range of treatment duration (3-10 years), intervention costs (pound 300-400/year) and offset times (0-15 years). Data on costs and risks were from the UK. Costs included direct costs, but excluded indirect costs due to morbidity. A threshold for cost-effectiveness of pound 30,000/QALY gained was used. With the base case ( pound 350 per year; 35% efficacy) treatment in women was cost-effective with a 10-year hip fracture probability that ranged from 1.1% at the age of 50 years to 9.0% at the age of 85 years. Intervention thresholds were sensitive to the assumed costs and offset time. The exclusion of osteoporotic fractures other than hip fracture significantly increased the cost-effectiveness ratio because of the substantial morbidity from such other fractures, particularly at younger ages. Cost-effective scenarios were found for women at the threshold for osteoporosis from the age of 60 years. Treatment of established osteoporosis was cost-effective irrespective of age. We conclude that the inclusion of all osteoporotic fractures has a marked effect on intervention thresholds, that these vary with age and that available treatments can be targeted cost-effectively to individuals from the UK at moderately increased fracture risk.

Entities:  

Mesh:

Year:  2004        PMID: 15663999     DOI: 10.1016/j.bone.2004.08.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  37 in total

Review 1.  The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

2.  BMD, clinical risk factors and their combination for hip fracture prevention.

Authors:  H Johansson; J A Kanis; A Oden; O Johnell; E McCloskey
Journal:  Osteoporos Int       Date:  2009-03-17       Impact factor: 4.507

3.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 4.  Bone fragility in men--where are we?

Authors:  E Seeman; G Bianchi; S Khosla; J A Kanis; E Orwoll
Journal:  Osteoporos Int       Date:  2006-08-01       Impact factor: 4.507

Review 5.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

6.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

7.  Improving osteoporosis management in general practice: a pharmacist-led drug use evaluation program.

Authors:  Edwin C K Tan; Johnson George; Kay Stewart; Rohan A Elliott
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 3.923

8.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

Authors:  B Dawson-Hughes; A N A Tosteson; L J Melton; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

9.  Cost-effective osteoporosis treatment thresholds: the United States perspective.

Authors:  A N A Tosteson; L J Melton; B Dawson-Hughes; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.